NCI/LinkedIn
Dec 26, 2024, 15:10
Eliminating cancer with nivolumab and the chemotherapy regimen AVD – NCI
National Cancer Institute (NCI) shared a post on LinkedIn:
“In a large clinical trial, treatment with nivolumab (Opdivo) and the chemotherapy regimen AVD was better at eliminating cancer and keeping it at bay than the current standard initial treatment for the disease, AVD and brentuximab (Adcetris). The nivolumab combination also had fewer side effects.
Media Description: An imaging scan of a man with advanced Hodgkin lymphoma, showing multiple areas with cancer (red and yellow-orange) throughout the upper body. Credit: Courtesy of Pranav Sharma, Radiopaedia.org. CC BY-NC-SA 3.0.”
More posts featuring National Cancer Institute.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 26, 2024, 15:12
Dec 26, 2024, 15:10
Dec 26, 2024, 15:03
Dec 26, 2024, 15:03
Dec 26, 2024, 14:55
Dec 26, 2024, 14:47
Dec 26, 2024, 14:44